Firms Hope To Adapt COVID Vaccine Trial Design, FDA Communication Approaches To Other Diseases

Moderna has adopted more inclusionary enrollment criteria and real-time epidemiology monitoring for its RSV vaccine program, while Pfizer is expanding its internal ‘Lightspeed’ approach. US FDA is considering how to extend the fast, frequent and informal interactions.

Pruning a bush
The design of Moderna's Phase III vaccine trial was pruned to answer the most important scientific questions. • Source: Alamy

More from R&D

More from Pink Sheet